Working… Menu
Trial record 46 of 115 for:    "Viral Infectious Disease" | "Ledipasvir"

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02836925
Recruitment Status : Recruiting
First Posted : July 19, 2016
Last Update Posted : June 28, 2019
Information provided by (Responsible Party):
Fondazione Italiana Linfomi ONLUS

Brief Summary:
This is a non-randomized, a single arm, phase II multicentre study of sofosbuvir plus ledipasvir (genotype 1 and 4) or sofosbuvir plus velpatasvir (genotype 2 and 3) for patients with hepatitis C virus-associated indolent B-cell lymphomas (HCV-RNA positive).

Condition or disease Intervention/treatment Phase
Indolent B-cell Lymphoma Hepatitis C Drug: Ledipasvir+Sofosbuvir Drug: Sofosbuvir+Velpatasvir Phase 2

Detailed Description:
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas
Study Start Date : March 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : May 2022

Arm Intervention/treatment
Experimental: Ledipasvir+Sofosbuvir,Sofosbuvir+Velpatasvir
The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated
Drug: Ledipasvir+Sofosbuvir

Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg

  • 12 weeks in previously untreated infected patients
  • 24 weeks for previously treated patients with uncertain subsequent retreatment options
Other Name: Harvoni

Drug: Sofosbuvir+Velpatasvir

Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg

· 12 weeks of treatment

Other Name: Epclusa

Primary Outcome Measures :
  1. SVR12 [ Time Frame: 12 weeks from the end of the treatment ]
    Sustained virologic response (SVR12) defined as undetectability of HCV-RNA 12 weeks after completion of antiviral therapy

Secondary Outcome Measures :
  1. ORR [ Time Frame: 12 weeks from the end of treatment ]
    Overall response rate (ORR) of lymphoma: CR is defined by the complete disappearance of all detectable sites and symptoms; PR is defined as a more than 50% reduction. Responses different from CR/PR are defined as stable disease (SD); progressive disease (PD) is considered an increase in size of more than 50% of previously documented disease or the appearance of new lesions. Lymphoma response will be assessed 12 weeks after the end of antiviral treatment

  2. PFS [ Time Frame: 36 months ]
    Progression‐free survival (PFS) defined as the time between enrolment and progression or relapse or death from any cause.

  3. EFS [ Time Frame: 36 months ]
    Event‐free survival (EFS) defined as time between enrolment and failure of treatment or death as a result of any cause

  4. OS [ Time Frame: 36 months ]
    Overall survival (OS) defined as the time between enrolment and death from any cause

  5. ORR for lymphoma [ Time Frame: 12 weeks from the end of treatment ]
    ORR for lymphoma according to Matutes criteria (Matutes et al, Leukemia 2008) only in patients with splenic-marginal zone lymphoma (SMZL)

  6. Rapid virological response [ Time Frame: 4 weeks ]
    rapid virologic response (RVR)

  7. Extended rapid virological response [ Time Frame: 4 weeks ]
    extended RVR (eRVR)

  8. Early virological response [ Time Frame: 4 weeks ]
    early virologic response (EVR)

  9. Toxicity - Incidence of Adverse Events [ Time Frame: 12 months ]
    toxicity will be classified according to definitions of Common Terminology Criteria for Adverse Event version 4.03 (CTCAE). It will be determined by the incidence of severe, life‐threatening (CTCAE grade 3, 4 and 5) and/or serious adverse events

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age >18 years
  2. Indolent B cell lymphoma including: marginal zone lymphoma (nodal, extranodal, splenic and disseminated), lymphoplasmacytic lymphoma, small lymphocytic lymphoma, follicular lymphoma grade 1 and 2, CD5‐negative B‐cell lymphoma NOS
  3. HCV‐RNA positivity
  4. Assessable HCV genotype
  5. No previous therapy for the lymphoma
  6. Measurable disease after diagnostic biopsy (longest axis ≥1.5 cm for nodal and ≥1 cm for extranodal lesions) and/or evaluable disease (quantifiable BM infiltrate and ≥5 x 109/l clonal B-cell in peripheral blood in case of exclusive BM/leukemic disease in CD5-negative Bcell lymphoma NOS)
  7. No need of immediate lymphoma treatment defined as absence of all the following criteria: systemic symptoms, bulky nodal or extranodal mass (>7 cm), symptomatic splenomegaly, progressive leukemic phase, serous effusions
  8. Performance status <2 according to ECOG scale
  9. Adequate hematological counts: ANC >1 x 109/L, hemoglobin >9 g/dl (transfusion independent), platelet count > 50 x 109/L (transfusion independent)
  10. No central nervous system (CNS) disease (meningeal and/or brain involvement by lymphoma)
  11. Adequate kidney function (creatinine clearance ≥ 45 ml/min)
  12. Cardiac ejection fraction ≥45% (echocardiography or MUGA scan)
  13. Normal lung function
  14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS
  15. Non major surgical intervention prior 3 months to enrolment if not due to lymphoma and/or no other disease life‐threatening that can compromise chemotherapy treatment
  16. Disease free of prior malignancies other than lymphoma for >3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  17. Life expectancy > 6 months
  18. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
  19. Written informed consent
  20. Women must be:

    • postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
    • surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
    • completely abstinent (at the discretion of the investigator/per local regulations) (periodic abstinence from intercourse is not permitted) or
    • if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double‐barrier method (eg: condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
  21. Women of childbearing potential must have a negative serum or urine beta‐human chorionic gonadotropin (beta-hCG) pregnancy test at screening
  22. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 1 month after receiving the last dose of study drug if not taking ribavirin of for 6 months after receiving the last dose of study drug if taking ribavirin.

Exclusion Criteria:

  1. Diagnosis of lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma grade 3, primary mediastinal B-cell lymphoma
  2. Previous anti-HCV treatment with sustained virological response
  3. Diagnosis of cirrhosis (histological or Stiffness >12 KpA)
  4. CNS disease (meningeal and/or brain involvement by lymphoma)
  5. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
  6. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug)
  7. Concomitant therapy with amiodarone
  8. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
  9. Cardiac ejection fraction <45% (MUGA scan or echocardiography).
  10. Creatinine clearance <45 ml/min
  11. Presence of major neurological disorders
  12. HIV positivity, HBV positivity (HbsAg+ or HBV-DNA+) with the exception of HBcAb+, HbsAg-, HBsAb+/- patients with HBV-DNA negativity
  13. Ongoing systemic bacterial, fungal or viral infections at the time of initiation of study treatment (defined as requiring therapeutic dosing of an antimicrobial, antifungal or antiviral agent)
  14. Major surgical intervention prior 3 months to enrollment if not due to lymphoma and/or other
  15. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
  16. Life expectancy <6 months
  17. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
  18. If female, the patient is pregnant or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02836925

Layout table for location contacts
Contact: Uffici Studi FIL Fondazione Italiana Linfomi 0039 ext 0131206288

Layout table for location information
A.O. Spedali Civili Recruiting
Brescia, BS, Italy, 25100
Contact: Marina Motta, MD    +39 0303996269   
Principal Investigator: Marina Motta, MD         
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Not yet recruiting
Milano, MI, Italy, 20122
Contact: Luca Baldini, MD    0039 02 55033334   
Principal Investigator: Luca Baldini         
Irccs Centro Di Riferimento Oncologico (Cro) Recruiting
Aviano, Pordenone, Italy, 33801
Contact: Michele Spina   
Principal Investigator: Michele Spina, MD         
Ospedale San Bortolo Recruiting
Vicenza, VI, Italy, 36100
Contact: Carlo Visco, MD    +39 0444-753626/3518;   
Principal Investigator: Carlo Visco, MD         
Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona Not yet recruiting
Verona, VR, Italy, 37126
Principal Investigator: Dino Veneri, MD         
A.O. Universitaria Careggi Di Firenze Not yet recruiting
Firenze, Italy, 50139
Contact: Luigi Rigacci         
Principal Investigator: Luigi Rigacci, MD         
Sc Ematologia Ao Niguarda Ca' Granda Not yet recruiting
Milano, Italy, 20162
Contact: Alessandra Tedeschi   
Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori Recruiting
Milano, Italy
Principal Investigator: Anna Dodero, MD         
Ospedale San Raffaele Ematologia Recruiting
Milano, Italy
Principal Investigator: Andrés Ferreris, MD         
IRCCS Fondazione Pascale Not yet recruiting
Napoli, Italy, 80131
Principal Investigator: Antonello Pinto, MD         
U.O. Ematologia AO di Padova Recruiting
Padova, Italy
Contact: Francesco Piazza   
Principal Investigator: Francesco Piazza         
Policlinico P.Giaccone Not yet recruiting
Palermo, Italy
Principal Investigator: Emilio Iannitto, MD         
A.O. Universitaria Di Parma Recruiting
Parma, Italy, 43126
Principal Investigator: Francesca Re, MD         
Ematologia Policlinico San Matteo Recruiting
Pavia, Italy, 27100
Contact: Luca Arcaini, M.D.    00390382503595   
Principal Investigator: Luca Arcaini, M.D.         
Ospedale Civile Piacenza Recruiting
Piacenza, Italy
Contact: Daniele Vallisa, MD   
Principal Investigator: Daniele Vallisa         
Ematologia - Policlinico Umberto I Università Sapienza Recruiting
Roma, Italy
Contact: Alessandro Pulsoni   
Principal Investigator: Alessandro Pulsoni         
Dipartimento di Oncologia Medica ed Ematologia, Istituto Humanitas Recruiting
Rozzano, Italy
Contact: Armando Santoro, MD         
Principal Investigator: Armando Santoro, MD         
AOU Città della Salute e della Scienza di Torino Recruiting
Torino, Italy, 10126
Contact: Lorella Orsucci, MD   
Principal Investigator: Lorella Orsucci, MD         
A.O. Universitaria S. Maria Della Misericordia Di Udine Not yet recruiting
Udine, Italy, 33100
Principal Investigator: Francesco Zaja, MD         
Ospedale di Circolo e Fondazione Macchi Recruiting
Varese, Italy
Principal Investigator: Michele Merli, MD         
Sponsors and Collaborators
Fondazione Italiana Linfomi ONLUS
Layout table for investigator information
Principal Investigator: Luca Arcaini Policlinico San Matteo Pavia Fondazione IRCCS

Layout table for additonal information
Responsible Party: Fondazione Italiana Linfomi ONLUS Identifier: NCT02836925     History of Changes
Other Study ID Numbers: FIL_BArT
First Posted: July 19, 2016    Key Record Dates
Last Update Posted: June 28, 2019
Last Verified: June 2019
Keywords provided by Fondazione Italiana Linfomi ONLUS:
hepatitis C
Indolent B-cell lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Virus Diseases
RNA Virus Infections
Ledipasvir, sofosbuvir drug combination
Hepatitis A
Hepatitis C
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Enterovirus Infections
Picornaviridae Infections
Flaviviridae Infections
Lymphoma, Non-Hodgkin
Sofosbuvir-velpatasvir drug combination
Antiviral Agents
Anti-Infective Agents